Non-melanoma skin cancers in ruxolitinib-treated MPN patients behave aggressively, with adverse features and high recurrence. In our cohort, mortality from metastatic NMSC exceeded that from myelofibrosis . Vigilant skin assessment, counselling on NMSC risks, and prospective ruxolitinib-NMSC studies are crucial.

Subjects:
Myeloid Neoplasia
This content is only available as a PDF.
Copyright © 2023 American Society of Hematology
2023

Article PDF first page preview

Article PDF first page preview
You do not currently have access to this content.
Sign in via your Institution